Treprostinil not checked

United Therapeutics · UT-15C · UT 15

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
5 active
20 in total · 3 in the EU
Targets
—
None known yet

What this is

How it works
Prostacycline Vasodilator FDA class
How it’s given
“Parenteral treprostinil will be administered per schedule specified in the arm description.”In the company’s words, NCT05203510 on ClinicalTrials.gov
Tested for
Progressive Pulmonary Fibrosis (2 trials), Interstitial Lung Disease (2 trials), Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (2 trials), Pulmonary Arterial Hypertension, Idiopathic Pulmonary Fibrosis
Main trialPhase 4
“The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).”In the company’s words, NCT05203510 on ClinicalTrials.gov
Other names
Remodulin · Orenitram · UT-15C · UT 15 · Flolan · Tyvaso

Other drugs for Progressive Pulmonary Fibrosis

All 42 drugs for Progressive Pulmonary Fibrosis

Copies tested against it1

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up4

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials20

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 30 Apr 2026 A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
Phase 3Recruiting Nov 2027 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Phase 3Enrolling by invitation Dec 2029 Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Phase 2/3Not yet recruiting Sep 2034 An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Phase 2Not yet recruiting May 2028 Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Phase 4Terminated Sep 2009 Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH
Phase 4Terminated Jan 2010 Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
Phase 4Completed 25 Feb 2014 TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
Phase 4Completed 11 May 2022 EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension
Phase 3Completed Oct 2007 Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
Phase 3Completed 12 Feb 2020 An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
Phase 3Terminated 13 Oct 2022 A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
Phase 3Terminated 29 Nov 2022 Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
Phase 3Completed 30 Jun 2025 Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Phase 3Completed 2 Feb 2026 Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
Phase 2/3Withdrawn Jun 2010 Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients
Phase 2/3Completed 26 Dec 2019 Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
Phase 2/3Terminated 1 Aug 2021 An Open Label Extension Study to Evaluate Inhaled Treprostinil in Adult PH With ILD Including CPFE
Phase 2Completed 20 Jul 2017 Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
Phase 2Terminated 27 Sep 2022 Remodulin as Add-on Therapy for the Treatment of Persistent Pulmonary Hypertension of the Newborn
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Treprostinil

Following is part of Solo: you see every change to Treprostinil the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in